Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs
A phase II study of Zimberelimab anti PD1 immunOtherapy +/- Domvanalimab anti-TIGIT therapy in resectable mismatch repair deficient gastric/gastro-oesophageal junctional AdenoCarinoma (ZODIAC)
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Kai-Keen Shiu (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
ZODIAC: A randomised phase II study of Zimberelimab anti-PD1 immunOtherapy +/- Domvanalimab anti-TIGIT immunotherapy in resectable mismatch repair deficient gastric and gastro-oesophageal junctional AdenoCarcinoma
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
Original classification
CancerPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know